Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450

European Journal of Pharmacology

Volumn 485, Issue 1-3, 2004, Pages 145-158

  Chaki, Shigeyuki ^a   Nakazato, Atsuro ^a   Kennis, Ludo ^b   Nakamura, Masato ^a   MacKie, Claire ^b   Sugiura, Masayuki ^a   Vinken, Petra ^b   Ashton, David ^b   Langlois, Xavier ^b   Steckler, Thomas ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Anxiety; CRF (corticotropin releasing factor); CRF1 receptor; Depression; R278995 CRA0450; Stress related behavior

Indexed keywords

1 [8 (2,4 DICHLOROPHENYL) 2 METHYLQUINOLIN 4 YL] 1,2,3,6 TETRAHYDROPYRIDINE 4 CARBOXAMIDE BENZENESULFONATE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; N ALLYLNORMETAZOCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; MALE; MAZE TEST; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SWIMMING; TRANQUILIZING ACTIVITY;

EID: 1642456601     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.032     Document Type: Article

References (55)

1. Bakshi V.P., Smith-Roe S., Newman S.M., Grigoriadis D.E., Kalin N.H. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRF2) receptors in lateral septum or CRF1 receptors in amygdala. J. Neurosci. 22:2002;2926-2935.
2. Bilezikjian L.M., Vale W.W. Glucocorticoids inhibit corticotropin- releasing factor-induced production of adenosine 3′, 5′- monophosphate in cultured anterior pituitary cells. Endocrinology. 113:1983;657-662.
3. Bissette G. Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats. Pharmacol. Biochem. Behav. 69:2001;269-281.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Chaki S., Okuyama S., Nakazato A., Kumagai T., Okubo T., Ikeda Y., Oshida Y., Hamajima Y., Tomisawa K. In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001. Eur. J. Pharmacol. 371:1999;205-211.
6. Chaki S., Steckler T., Ashton D., Kennis L., Nakazato A., Langlois X. R278995/CRA0450, a novel selective CRH1 receptor antagonist: receptor binding, signal transduction, functional activity and ex-vivo autoradiography. Abstr.-Soc. Neurosci. 683.2:2002.
7. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.L., Chrousos G.P., Webster E., Gold P.W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. 140:1999;79-86.
8. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 7:1987;88-100.
9. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. 121:1995;66-72.
10. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
11. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz H., Northrop J.P., Ringold G.M., Danielsen M. Lipofectin: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7413-7417.
12. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Psychopharmacology. 138:1998;55-66.
13. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. 4-(2-chloro-4-methoxy-5- methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl] 5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
14. o-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2α receptors. Mol. Pharmacol. 50:1996;679-686.
15. Guimaraes F.S., Carobrez A.P., De Aguiar J.C., Graeff F.G. Anxiolytic effect in the elevated plus-maze of the NMDA receptor AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology. 103:1991;91-94.
16. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., Darre V., Marcy C., Rouby P.E., Simiand J., Guitard J., Gout G., Steinberg R., Rodier D., Griebel G., Soubrie P., Pascal M., Pruss R., Scatton B., Maffrand J.P., Le Fur G. 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotropin-releasing factor (1) receptor antagonist: I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 301:2002;322-332.
17. Gutman D.A., Owens M.J., Nemeroff C.B. Corticotropin-releasing factor antagonists as novel therapeutics. Drug Future. 25:2000;923-931.
18. Gutman D.A., Owens M.J., Skelton K.H., Thrivikraman K.V., Nemeroff C.B. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J. Pharmacol. Exp. Ther. 304:2003;874-880.
19. Hammack S.E., Richey K.J., Schmid M.J., LoPresti M.L., Watkins L.R., Maier S.F. The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J. Neurosci. 22:2002;1020-1026.
20. Hauger R.L., Grigoriadis D.E., Dallman M.F., Plotsky P.M., Vale W.W., Dautzenberg F.M. International union of pharmacology: XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55:2003;21-26.
21. Heinrichs S.C., Merlo-Pich E., Miczek K.A., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
22. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21.
23. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigodiaris D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 27:2002;194-202.
24. Herbert J. Trimble M.R., Zanifan E. Behavior and the limbic system with particular reference to sexual and aggressive interactions. 1985;51-67 Oxford Univ. Press, Oxford.
25. Holsboer F., Von Bardeleben U., Gerken A., Stalla G.K., Muller O.A. Blunted corticotropin and normal cortisol response to human corticotropin- releasing factor in depression. New Engl. J. Med. 311:1984;1127-1133.
26. Kamei H., Kameyama T., Nabeshima T. (+)SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated sigma 1 sites. Eur. J. Pharmacol. 309:1996;149-158.
27. Kinsora J.J. Jr., Corbin A.E., Snyder B.J., Wiley J.N., Meltzer L.T., Heffner T.G. Effects of igmesine in preclinical anti-depressant test. Abstr.-Soc. Neurosci. 24:1998;291.3.
28. Kostich W.A., Chen A., Sperle K., Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2 gamma receptor. Mol. Endocrinol. 12:1998;1077-1085.
29. Leadbetter R., Pande A., Slomkowski M., Smith F. Igmesine: a novel antidepressant. Biol. Psychiatry. 45:1999;76S. (suppl., Abs. Z44).
30. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U. S. A. 92:1995;836-840.
31. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J.L. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
32. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
33. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. Anxiolytic properties of the selective, nonpeptidergic CRF1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
34. Mudunkotuwa N.T., Horton R.W. Desipramine administration in the olfactory bulbectomized rat: changes in brain β-adrenoceptor and 5-HT2A binding sites and their relationship to behavior. Br. J. Pharmacol. 117:1996;1481-1486.
35. Nemeroff C.B., Widerlov E., Bissette G., Wallens H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
36. Noda Y., Kamei H., Kamei Y., Nagai T., Nishida M., Nabeshima T. Neurosteroids ameliorate conditioned fear stress: an association with sigma1 receptors. Neuropsychopharmacology. 23:2000;276-284.
37. Okuyama S., Imagawa Y., Ogawa S., Araki H., Ajima A., Tanaka M., Muramatsu M., Nakazato A., Yamaguchi K., Yoshida M., Otomo S. NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci. 53:1993;PL285-PL290.
38. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A., Kumagai T., Okubo T., Tomosawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
39. Owen M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin releasing factor. Pharmacol. Rev. 43:1991;425-473.
40. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W.W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2969-2973.
41. Rivier C., Plotsky P.M. Mediation by corticotropin-releasing factor (CRF) of adrenohypophysial hormone secretion. Annu. Rev. Physiol. 48:1986;475-494.
42. Ronan P.J., Kramer G.L., Kram M.L., Petty F. CRF in the learned helplessness animal model of depression: acute and prior administration of CRF causes escape deficits in rats similar to those induced by inescapable stress. Abstr.-Soc. Neurosci. 26:2000;2266.
43. Shibata S., Nakanishi H., Watanabe S., Ueki S. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol. Biochem. Behav. 21:1984;225-230.
44. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type 1) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
45. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry. 46:1999;1480-1508.
46. Steckler T., Bakker M.H.M., Kennis L., Okuyama S., Nakazato A., Chaki S. Antagonism of stress-induced anxiety and antidepressant-like profile of the selective CRH1 antagonist R278995/CRA0450. Abstr.-Soc. Neurosci. 683.1:2002.
47. Takahashi L.K., Ho S.P., Livanov V., Graciani N., Arneric S.P. Antagonism of CRF2 receptor produces anxiolytic behavior in animal models of anxiety. Brain Res. 902:2001;135-142.
48. Takamori K., Kawashima N., Chaki S., Nakazato A., Okuyama S. Involvement of corticotropin-releasing factor subtype I receptor in the acquisition phase of learned helplessness in rats. Life Sci. 69:2001;1241-1248.
49. Taylor A.L., Fishman L.M. Corticotropin-releasing hormone. New Engl. J. Med. 319:1988;213-222.
50. Thorne B.M., Rowles J.S. Memory deficit in passive-avoidance learning in bulbectomized Long-Evans hooded rats. Physiol. Behav. 44:1988;339-345.
51. Timpl P., Spanagel R., Silaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19:1998;162-166.
52. Ukai M., Meada H., Nanya Y., Kameyama T., Matsuno K. Beneficial effects of acute and repeated administrations of σ receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav. 61:1998;247-252.
53. Urani A., Roman F.J., Phan V.-L., Su T.-P., Maurice T. The antidepressant-like effect induced by σ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther. 298:2001;1269-1279.
54. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41-amino acid residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
55. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiat. Res. 34:2000;171-181.